Phase I/II trial of CG0070 plus anti-CTLA-4 checkpoint inhibitor as a neo-adjuvant immunotherapy in patients with muscle invasive bladder cancer

Trial Profile

Phase I/II trial of CG0070 plus anti-CTLA-4 checkpoint inhibitor as a neo-adjuvant immunotherapy in patients with muscle invasive bladder cancer

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs CG 0070 (Primary) ; Anti-CTLA-4 monoclonal antibody
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms NAOMI
  • Most Recent Events

    • 21 Oct 2015 New trial record
    • 19 Oct 2015 According to a Cold Genesys media release, the U.S. FDA has accepted a phase I/II trial of CG0070 plus an anti-CTLA-4 checkpoint inhibitor as a neo-adjuvant immunotherapy for muscle invasive bladder cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top